GlaxoSmithKline chops up mature drugs portfolio for $3B sale

GlaxoSmithKline ($GSK) may be hitting obstacles all over the world, what with bribery fines and probes, Advair rivals in Europe, and the like. But the U.K. drugmaker has managed to make progress on its plan to offload some of its older products: It's planning to sell off chunks of the portfolio in geographic areas, with Denmark's Lundbeck and India's Lupin are said to be in the running for regional pieces, likely in the U.S. Report

Suggested Articles

Cardiac risks associated with roxadustat are comparable to placebo in nondialysis patients and to Amgen's standard, Epogen, in those on dialysis.

Pfizer and Merck KGaA's immuno-oncology agent Bavencio failed another gastric cancer study, this time as a maintenance treatment after chemotherapy.

A jury ordered Biogen to pay nearly $6 million to a former sales manager who reported a colleague's misconduct and got fired a few months later.